Redbud Medicine is a Delaware-headquartered clinical contract research organization (CRO) offering science-based clinical development services. It provides full-service development from bench to bedside, aiming to reduce traditional clinical study timelines, improve overall quality, and contain costs. The company’s global team has extensive experience across a broad range of therapeutic areas and global clinical development. Services include protocol design, case report form (CRF) creation, ongoing medical review through the final clinical study report (CSR), plus digital solutions and training for sponsors new to drug development. Redbud plans to use the Series A proceeds to streamline execution of clinical trials across those stages. The article reports the company raised $10M in Series A funding.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2022